Hisun Biomaterials 海正生材 (SSE 688203)
Профиль
Zhejiang Hisun Biomaterials Co., Ltd. (Hisun Biomaterials) is a high-tech enterprise specializing in the research, production, and sales of polylactic acid (PLA). Founded in August 2004 and headquartered in Taizhou, Zhejiang, China, the company is a pioneer in the Chinese PLA industry, having developed proprietary technology for the industrial production of lactide and the full-process polymerization of PLA.
The company is listed on the Shanghai Stock Exchange STAR Market (688203). Its core products include pure PLA resin and composite modified PLA, which are used in packaging, food containers, tableware, non-woven fabrics, and 3D printing filaments.
As of 2026, the company remains active. In May 2026, it commissioned the first phase (75kt/a) of a 150kt/a PLA project through its subsidiary, Hitrend. The company maintains a strong market position as a national-level specialized “Little Giant” enterprise and the primary drafter of China’s national PLA standards. For the 2025 fiscal year, the company reported approximately 852 million CNY in revenue.
Sources#
- Development Journey_Zhejiang Hisun Biomaterials Co., Ltd-PLA,Plant resources
- About Us-Zhejiang Hisun Biomaterials Co., Ltd-PLA,Plant resources
- 关于我们-浙江海正生物材料股份有限公司-专注聚乳酸的研发、生产及销售
- 7 2025 9,865,281.03元。截至2025 年12 月31 日,公司母公司报表未分配利润为-19,050,126.05 鉴于公司2025 因素综合考虑,为更好的维护全体股东的长远利益,保障公司的可持续发展和资金需求,公司2025 √ 适用□
- Company profile_Zhejiang Hisun Biomaterials Co., Ltd.,PLA,Plant resources
- Hisun Biomaterials 2026 Company Profile: Stock Performance & Earnings | PitchBook
- Zhejiang Hisun Biomaterials Co Ltd, 688203:SHH profile - FT.com
- 海正生材:浙江海正生物材料股份有限公司2025年年度报告摘要-定期财报-慧博资讯 — 2026-04-14
- Отрасль
- Биопереработка, Промышленная химия, Упаковка и пластики, Текстиль и кожа
- Темы
- PLA (полимолочная кислота)
- Роль
- Производитель — “…resources, with integrated manufacturing capabilities from resin extrusion to finished components. - Location…”
Биорешения, которые поставляет 0
Пока не указана поставщиком в решениях с доказательствами.
Что предлагают
Продукты: 聚乳酸树脂
Сертификаты: FDA; TUV; BPI; DIN CERTCO
- Применение
- 3D打印 · 挤出,热吸塑成型 · 挤吹和注吹成型 · 膜类和淋膜 · 纤维无纺布 · 注塑成型
- Сертификаты (сайт)
- FDA · TUV · BPI · DIN CERTCO
- Производственные площадки
- Taizhou Bay New District, Taizhou, Zhejiang Province, China — 125,000 tons annually; PLA (Polylactic Acid) · Taizhou, Zhejiang Province, China — 75,000 tons; PLA - Under Construction · Taizhou Bay New District, Zhejiang Province, China — PLA Materials · 浙江省台州市台州湾新区台州湾大道188号 — PLA
- Продукты (сайт)
- 聚乳酸树脂 — 聚乳酸,全名Poly Lactic Acid(PLA)或Polylactide,是以乳酸或乳酸的二聚体丙交酯为单体,通过一系列的化学反应得到的高分子聚酯型材料,属于人工合成高分子材料,具有生物基和可降解的特点。
Прочитано на сайте компании: about · production · quality · rnd · contact
Новости и статус 6
- 2026-05 Последний статус: В 2026 г. компания вела обычную корпоративную деятельность: выборы совета директоров, назначения руководителей, пуск новых производственных мощностей. ↗ ↗ ↗
- 2026-07-28 二次创业 奋斗有我 | 马鸣赴海正生材走访调研海正生材(Hisun Biomaterials)是全球聚乳酸领域的龙头企业,全球产能位居第二,拥有完整的“乳酸—丙交酯—聚乳酸”产业链及自主技术;中国石化资本对其于2020年战略投资,2022年在科创板上市,当前正加快3D打印耗材与生物材料领域的布局与扩张。
- 2026-09-07 海正生材获机构调研,包括中信证券、华福证券、东北证券、宁波泽添基金、中信金石等10家机构-财经-金融界海正生材(Hisun Biomaterials)近期披露接待机构调研,透露聚乳酸(PLA)产能12.5万吨/年及子公司海诺尔5万吨、海创达7.5万吨产线的产能爬坡与在产率提升;公司今年上半年3D打印领域收入占比约49%,并计划在2028年12月前完成年产15万吨聚乳酸二期扩产,推进原料供应保障与定制改性服务。
- 2026-08-25 同花顺财经海正生材(Hisun Biomaterials)上半年业绩大幅增长,归母净利润和扣非净利润分别大增约558%和772%,主因是年产15万吨聚乳酸项目一期投产带来产能释放与毛利回升,3D打印应用成为最大增长点,境内销量与3D打印相关销量均显著提升,研发投入同比增30%。公司具备年产12.5万吨聚乳酸树脂产能,未来将推进募投与高性能生物基材料的前瞻研发。
- 2026-08-26 海正生材净利大涨557% - 资讯 - 中国化工信息周刊网海正生材(Hisun Biomaterials)上半年业绩大幅提升,净利润同比增57.6%至2092.2万元,扣非后增幅达771.9%;营业收入6.06亿元,增长48.5%。聚乳酸树脂产能从5万吨增至12.5万吨,销量大增,3D打印等应用增量显著,研发投入和专利持续增加。
- 2026-01-12 海正生材(688203):国内PLA市占第一 3D打印拓宽增长极 - FutubullHisun Biomaterials (海正生材) is a high-tech PLA producer with a dominant domestic market share, ongoing capacity expansion including a 0.15 Mt/year PLA project, and rising revenue from pure PLA and PLA with modifiers; the expanding 3D printing market is expected …
- 2026-08-26 财报快递|海正生材2026上半年净利增557.61%,财务费用暴增22倍 - 投资逻辑解析 - 股百科Hisun Biomaterials (海正生材) 上半年净利润大增517%至约2,092万元,营业收入6.06亿元,主因聚乳酸产销增长及募投产能释放;同时财务费用剧增、应收账款与存货攀升及汇兑损失带来潜在风险,经营现金流改善明显,公司继续扩产并推进员工股权激励。
Связи: владельцы, партнёры, аналоги
Похожие компании
FUTERRO · TotalEnergies Corbion · 恒逸石化 Hengyi Petrochemicals · Formosa Chemicals & Fibre Corporation · The Supreme Industries Ltd · Toray Industries, Inc. · Shinkong Synthetic Fibers Corporation 新光合成纖維股份有限公司 · 台灣塑膠工業股份有限公司
Реквизиты и контакты
Контакты, руководители и юридические данные доступны участникам.
Войти как участник